ArticleFrontiers in immunology2019
NOD2 and TLR2 Signal via TBK1 and PI31 to Direct Cross-Presentation and CD8 T Cell Responses.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Xuebijing alleviates septic myocardial injury by inhibiting ferroptosis mediated by the ICAM1/TLR signaling pathway.Histology and histopathology · 2026Article
- SnRK2.6-mediated phosphorylation stabilizes proteasome regulator 1 (PTRE1) to enhance 26S proteasome activity and coordinate ABA signaling in Arabidopsis.Plant communications · 2026Article
- The roles and heterogeneity of CD8International journal of molecular medicine · 2026Review
- Gut microbial metabolites in cancer immunomodulation.Molecular cancer · 2025Review
- Identification of childhood-onset lupus nephritis through integrative bioinformatics: otoferlin as a novel biomarker.Pediatric research · 2025Article
- Nucleotide-Binding Oligomerization Domain 2 in Signaling, Immunity, and Mycobacterial Infection.Immunity, inflammation and disease · 2025Review
- Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.Journal of medicinal chemistry · 2024Article
- Topical N-phosphonacetyl-l-aspartate is a dual action candidate for treating non-melanoma skin cancer.Experimental dermatology · 2023Article
- Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines TheirJournal of medicinal chemistry · 2021Article
- IL-6 effector function of group 2 innate lymphoid cells (ILC2) is NOD2 dependent.Science immunology · 2021Article
- Inflammatory Bowel Disease Through the Lens of Single-cell RNA-seq Technologies.Inflammatory bowel diseases · 2020Review
- Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review.Pharmaceutics · 2020Review
- Identification of Immune Cell Landscape and Construction of a Novel Diagnostic Nomogram for Crohn's Disease.Frontiers in genetics · 2020Article
- NOD2/RIG-I ActivatingFrontiers in immunology · 2020Article
- Integrated Bioinformatics Analysis Identifies ELAVL1 and APP as Candidate Crucial Genes for Crohn's Disease.Journal of immunology research · 2020Article
- Distinct Subcellular Compartments of Dendritic Cells Used for Cross-Presentation.International journal of molecular sciences · 2019Review
- A Conserved Requirement forFrontiers in physiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
NOD2 and TLR2 recognize components of bacterial cell wall peptidoglycan and direct defense against enteric pathogens. CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.